StockNews.com Downgrades Atossa Therapeutics (NASDAQ:ATOS) to Sell

Atossa Therapeutics (NASDAQ:ATOS) was downgraded by research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Monday.

Other analysts also recently issued research reports about the company. Ascendiant Capital Markets increased their target price on Atossa Therapeutics from $6.25 to $6.50 and gave the company a “buy” rating in a research note on Wednesday, September 11th. HC Wainwright boosted their price objective on shares of Atossa Therapeutics from $6.00 to $7.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th.

Atossa Therapeutics Price Performance

Shares of NASDAQ ATOS remained flat at $1.28 during trading hours on Monday. 722,207 shares of the company traded hands, compared to its average volume of 1,076,344. The stock has a market cap of $161.03 million, a price-to-earnings ratio of -5.82 and a beta of 1.23. Atossa Therapeutics has a fifty-two week low of $0.67 and a fifty-two week high of $2.31. The business’s 50 day moving average is $1.44 and its 200 day moving average is $1.37.

Hedge Funds Weigh In On Atossa Therapeutics

Several institutional investors have recently bought and sold shares of the business. XTX Topco Ltd bought a new position in shares of Atossa Therapeutics in the second quarter valued at about $29,000. Intech Investment Management LLC bought a new position in Atossa Therapeutics in the third quarter valued at about $29,000. SG Americas Securities LLC boosted its holdings in Atossa Therapeutics by 254.3% during the third quarter. SG Americas Securities LLC now owns 41,849 shares of the company’s stock worth $64,000 after buying an additional 30,037 shares during the last quarter. Cetera Advisors LLC acquired a new position in shares of Atossa Therapeutics during the 1st quarter worth about $72,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Atossa Therapeutics in the 3rd quarter valued at approximately $75,000. Institutional investors own 12.74% of the company’s stock.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.